Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
189 SEK | -0.74% | -3.67% | +25.92% |
Apr. 29 | Nordic Shares Rose Monday; Ratos Series A Climbed Highest | DJ |
Apr. 26 | Nordic Shares Closed Up Friday; Medicover Series B Climbed Highest | DJ |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 56% by 2026.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company does not generate enough profits, which is an alarming weak point.
- The company is in debt and has limited leeway for investment
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 1077.72 times its estimated earnings per share for the ongoing year.
- The company appears highly valued given the size of its balance sheet.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+25.92% | 2.69B | B+ | ||
+17.73% | 83.47B | C+ | ||
-32.08% | 69.72B | B- | ||
-3.24% | 26.37B | C+ | ||
+4.13% | 17.86B | A- | ||
-13.68% | 16.83B | B | ||
+0.75% | 15.7B | A- | ||
+74.92% | 13.45B | C- | ||
+73.16% | 12.81B | C+ | ||
-2.02% | 12.44B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MCOV B Stock
- Ratings Medicover AB